Cellectis
CLLS
27 hedge funds and large institutions have $28.4M invested in Cellectis in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.06% less ownership
Funds ownership: 14.22% → 13.15% (-1.1%)
12% less capital invested
Capital invested by funds: $32.5M → $28.4M (-$4.04M)
16% less funds holding
Funds holding: 32 → 27 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.8K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.54K |
| 3 |
LPL Financial
San Diego,
California
|
+$249 |
| 4 |
Jones Financial Companies
Des Peres,
Missouri
|
+$178 |
| 5 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$174 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$1.9M |
| 2 |
BlackRock
New York
|
-$413K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$140K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$130K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$55.1K |
CLLS Hedge Fund Activity: Q2 2026 in Review
27 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q2 2026, worth a combined $28.4M — down 12% from $32.5M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CLLS and 3 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $14.8K. The largest seller was UBS AM, cutting an estimated $1.9M.
- 27 institutional investors held Cellectis (CLLS) as of Q2 2026, down from 32 in Q1 2026.
- Funds reported $28.4M of Cellectis stock for Q2 2026, down 12% quarter-over-quarter.
- 3 funds opened new Cellectis positions in Q2 2026 and 8 closed out, a net change of -5 holders.
- The largest Cellectis buyer in Q2 2026 was UBS Group, an estimated $14.8K added.
- The largest Cellectis seller in Q2 2026 was UBS AM, an estimated $1.9M sold.
Based on aggregated 13F filings for Q2 2026.